Microcin C7, a peptide antibiotic inhibitor of protein synthesis, is produced by Escherichia coli K-12 strains that carry the 43-kilobase low-copy-number plasmid pMccC7. Microcin C7 production and immunity determinants of this plasmid have been cloned into the vectors pBR322 and pACYC184. The resulting plasmids overproduce microcin C7 and express immunity against the microcin. Mcc-and Mcc-Imm-mutants have been isolated on recombinant plasmids by inserting transposable elements. Physical and phenotypic characterization of these mutants shows that a DNA region of 5 kilobases is required to produce microcin C7, and that two small regions located inside the producing region are also required to express immunity. Analysis of plasmids carrying mcc-lacZ gene fusions indicates that all microcin DNA is transcribed in the same direction. The results suggest that a structure like a polycistronic operon is responsible for microcin C7 production and immunity.
Microcin C7, a peptide antibiotic inhibitor of protein synthesis, is produced by Escherichia coli K-12 strains that carry the 43-kilobase low-copy-number plasmid pMccC7. Microcin C7 production and immunity determinants of this plasmid have been cloned into the vectors pBR322 and pACYC184. The resulting plasmids overproduce microcin C7 and express immunity against the microcin. Mcc-and Mcc-Imm-mutants have been isolated on recombinant plasmids by inserting transposable elements. Physical and phenotypic characterization of these mutants shows that a DNA region of 5 kilobases is required to produce microcin C7, and that two small regions located inside the producing region are also required to express immunity. Analysis of plasmids carrying mcc-lacZ gene fusions indicates that all microcin DNA is transcribed in the same direction. The results suggest that a structure like a polycistronic operon is responsible for microcin C7 production and immunity.
Microcins are dialyzable (i.e., low-molecular-weight) antibiotics produced by enterobacteria (1) . Strains producing a specific microcin are immune to the same microcin. As with colicins, both microcin production and immunity are encoded by plasmids, but unlike most colicins, the production of microcins is not inducible by DNA-damaging SOS agents (for a review, see reference 3). Hitherto, five types of microcins have been identified by cross-immunity, biochemical, and genetic criteria.
Most microcins are peptides. This is the case of microcin C7, formerly named microcin 7, which is the sole representative of the immunity group C. Microcin C7 was purified from the supernatants of stationary-phase cultures. Structural analysis showed that this microcin is a linear heptapeptide blocked at both ends. The proposed sequence for the native molecule is acetyl-Met-Arg-Thr-Gly-Asn-AlaAsp-X, where X represents an unidentified acid labile group which substitutes the terminal aspartic acid (13, 14) . Microcin C7 is a bacteriostatic agent that inhibits the growth of enterobacteria phylogenetically close to Escherichia coli, apparently by blocking protein synthesis (14) .
We are interested in the genetic control of synthesis of microcins. Studies on microcin B17, an inhibitor of DNA synthesis (20, 21) , have recently been published (15, 18, 19, 28, 29) . In this paper we present the first results on microcin C7. We show the involvement of a medium-size monocopy plasmid in the production of this microcin. The plasmid information required to synthesize this antibiotic and to ensure self-immunity has been mapped within a 5.0-kilobase (kb) region. The genetic organization and expression of this region are discussed.
MATERIALS AND METHODS
Bacterial strains, plasmids, and phages. The sources and characteristics of the organisms and plasmids employed are listed in Table 1 .
Media and chemicals. Liquid and solid LB medium and M63 minimal medium were prepared essentially as described by Miller (27) . Minimal medium was supplemented with * Corresponding author. glucose (0.2%) and vitamin Bi (1 ,ug/ml). Antibiotics were used at the following final concentrations: ampicillin, 40 ,ug/ml; tetracycline, 20 ,ug/ml; kanamycin, 20 ,ug/ml; streptomycin, 100 ,g/ml; nalidixic acid, 40 ,ug/ml; chloramphenicol 20 ,ug/ml. The indicator 5-bromo-4-chloro-3-indolyl-Dgalactopyranoside was added to plates at 20 ,ug/ml.
Microcin C7 production and immunity tests. Microcin production was assayed by stabbing single colonies onto a lawn of sensitive cells. After overnight incubation, the microcin C7-producing colonies had a clear growth inhibition zone around them. To determine the immunity of a strain, a few fresh colonies of a microcin C7-producing strain were suspended in M63 minimal medium to obtain ca. 108 cells per ml. Drops of this suspension were placed on the surface of M63 agar plates and allowed to run on a straight line on the agar. When the streaks were dried, the plates were incubated at 37°C for 24 h; then single colonies were cross-streaked, and the plates were incubated. Only microcin-immune cells grew in the immediate vicinity of the producing bacteria.
Plasmid DNA manipulations. Plasmid DNA was usually obtained from alkali-lysed cells. DNA was cut with restriction endonucleases, and DNA fragments were ligated with T4 DNA ligase by using standard recipes. Analysis of DNA fragments was carried out in Tris-borate agarose gels with DNA fragments of known sizes as references. All of these techniques were described previously (26) .
Genetic methods. Conjugation was carried out as described by Miller (27) . Transformation of competent cells and selection of transformed bacteria with the desired phenotype were done as previously described (28) .
Isolation of insertions of transposon in plasmids. Tn3 transposon insertions in plasmids were isolated by introducing the plasmid into the strain SC18 cultivated at 30°C and selecting for the plasmid-mediated transfer of ampicillin resistance into strain pop3351 as described previously (28) . TnS insertions in pMccC7 were isolated by infecting strain MC4100 harboring pMccC7 with phage X467 and selecting for the plasmid-mediated transfer of kanamycin resistance into strain BM21 as described previously (29) . TnS insertions into small multicopy plasmids were obtained by infecting strain RYC1000 carrying the plasmid to be mutagenized with X467. After infection, samples were distributed in tubes containing 1 ml of fresh LB medium and incubated for 2 h. Samples of these cultures were spread on LB agar plates containing kanamycin, which were then incubated at 42°C overnight. The colonies were next washed off the plates with a small volume of LB broth. Plasmid DNA from these bacteria was isolated and used to transform strain RYC1000 with selection for resistance to kanamycin. Kmr transformants were checked for microcin production and microcin immunity. Then plasmid DNA was isolated, and the transposon insertion site was mapped by restriction endonuclease analysis.
Isolation of mccC7-lacZ gene fusion. lacZ gene fusions were obtained by mini Mu dII1681 transposition as described by Castilho et al. (9) . pCID104 was introduced into strain POII1681TR by transformation with selection for Cmr. The transformants were then thermally induced to produce phage particles which were used to infect strain RYC3001.6. Cmr Kmr transductants were selected at 30°C on LB agar plates containing antibiotics and 5-bromo-4-chloro-3-indolyl-Dgalactopyranoside. Blue colonies (Lac') were tested for microcin production and immunity, and then their plasmids were physically analyzed. ,-Galactosidase activity was assayed on exponentially growing cells in M63 medium and expressed as described by Miller (27) .
RESULTS
Characterization of plasmid pMccC7. In a previous paper it was reported that the wild-type microcin C7-producing strain BM7006 was apparently able to transfer this property to E. coli K-12 strains after mating (2) . To confirm this result we crossed BM7006 Strs and E. coli K-12 MC4100 Strr on LB agar without selective pressure. Bacteria were then restreaked on the same medium supplemented with streptomycin, and isolated colonies were checked for microcin production. The plasmid content of four colonies, two producers of microcin and two nonproducers, was compared with that of strain BM7006. Whereas nonproducer clones lacked plasmid DNA, a single plasmid species was found in producer MC4100 transconjugants. This plasmid, which was about 40 kb in size, was also found in the wild-type strain together with four more plasmids of about 100, 6.1, 5.6, and 2.5 kb, respectively (results not shown). We concluded that the genetic information for production of microcin C7 is borne by a transmissible plasmid which was called pMccC7. The plasmid also encodes for immunity against the microcin. Like other microcin plasmids, pMccC7 does not contain conventional antibiotic resistance markers but contains all of the information needed for self-transfer because it was transmitted by conjugation to strain BM21 from the above MC4100 transconjugants.
Plasmid DNA from MC4100(pMccC7) was isolated by dye-buoyant density centrifugation and then submitted to restriction analysis. Single and double DNA digests with endonucleases allowed us to construct the physical map shown in Fig. 1 . Ambiguities on the location of some restriction sites were resolved by analysis of recombinants containing fragments PstI B and HindlIl C and E in pBR322 (6) . According to these data, pMccC7 is 43 kb long.
Since pMccC7 lacks easily selectable markers, we obtained a set of derivative plasmids by insettion To determine the incompatibility group of plasmid pMccC7, pMM501, one of the pMccC7::TnS derivatives, was introduced by conjugation into BM21 cells carrying reference plasmids of different incompatibility groups (FI, FII, I1, Hi, H2, C, M, N, and X). In every case, transconjugants containing both plasmids were obtained. They were then grown for 50 generations in drug-free medium. Samples of cultures were plated out, and colonies were checked by replica plating for the presence of the antibiotic resistance characters encoded by the plasmids. We detected segregation of the resistance characters only with plasmid R6K, the reference plasmid of the IncX group (11) . Indeed, bacteria retained the Kmr character from pMM501, and most of them had lost the ampicillin resistance encoded by plasmid R6K. To exclude that the Kmr segregants were due to TnS transposition into the bla gene of R6K or into the bacterial chromosome we examined the plasmid content of five segregant colonies. All of them harbored only plasmid pMM501. It may be concluded that pMccC7 is a transmissible plasmid belonging to the IncX group. Elimination of pMccC7 by R6K was only achieved when selective pressure in favor of pMM501 was exerted. Similar results were reported by others concerning incompatibility between plasmid R6K and R485, an IncX plasmid of 56 kb (17, 22, 30 DNA precursor [methyl-3H]thymidine (J. C. Pdrez Dfaz, personal communication). Plasmid R485 has also been reported to be a low-copy-number plasmid (22, 30) . When pMM501 was transferred to strain RYC128 the plasmid was stably maintained, showihg that, like R6K, R485, and many other large plasmids, pMccC7 is capable of polA-independent replication in E. coli.
Cloning of microcin C7 determiiiants of plasmid pMccC7. To identify regions of pMccC7 encoding microcin C7 functions, we carried out two shotgun cloning experiments by using separately the endonucleases Psti and HindIII and the plasmid pBR322 (6) . The ligation mixtures were used to transform strain RYC1000. Transformants were examined for microcin production and microcin immunity. Of a total of 130 clones containing PstI fragments, none was a microcin producer, but three of them were immune to the antibiotic. When the plasmid content of these clones was studied, we found that all three carried the sanme unique plasmid species of 6.2 kb, which was called pMM560. This plasmid was composed of pBR322 and the 1.85-kb PstI E DNA fragment from pMccC7. The orientation of the cloned fragment within the bla gene of pBR322 was the same in all three recombinants.
More than 200 clones containing HindIII fragments were examined for microcin phenotype. Two of them were microcin immune and microcin overproducers. All others were Mcc-Imm-. Both Mcc+ clones harbored the same unique plasmid, which upon HindIll digestion generated three fragments. One of these was identical in size to HindIII-cleaved pBR322, and the other two were 5.65 and 2.55 kb long, respectively. The latter ones were the adjacent HindIII C and HindIII E fragments from pMccC7. Their relative atrangements in the hybrid plasmid, which was designated as pMM550, was identical to that found in the wild-type pMccC7 ( Fig. 1 and 2) . The HitidIII C fragment in pMM550 includes the 1.85-kb Pstt fragment in pMM56O.
Deletion analysis of plasniid pMM550. To obtain preliminary information on the location of the genetic determinants for microcin C7 synthesis on pMM550, we prepared plasmids deleted in vitro for different fragments of the cloned DNA. The structures and phenotypes of these derivatives are shown in Fig. 2 , which also includes some constructs id which the orientation of fragments was inverted. The DNA sequences of two HindIII fragments (C and E) are required to produce microcin and to ensure as much immunity as pMM550. The arrangement of these fragments in pMM550 and pMccC7 had to be maintained to produce the antibiotic and to express immunity, since a plasmid containing the fragments in a different order (pMM553; data not shown) was unable to synthesize microcin. This was confirmed by recloning these fragments from pMM550 in the unique HindIII site of vector pACYC184 (10) producing derivatives were Imm+ and vice versa, and all of them carried the two fragments arranged as in pMM550. One of them, called pCID104, was retained and used for the experiments described below.
Sequences near the right terminus of the smaller HindIII fragment are also essential for microcin production, since plasmid pMM572 did not produce it at all in spite of possessing all DNA to the left of the Ball site (Fig. 2) . DNA sequences located between the two BgIII sites inside the bigger HindIll fragment are also required to synthesize the antibiotic, since plasmids pMM570 (ABglII) and pMM571 (in which the fragment was inverted) were aiso Mcc. The known ( Fig. 2) (23) . Thus, by examining PstI and BglII digests of mutant plasmids we could deduce the location of Tn5 insertion sites.
Thirty-seven independent single TnS inserts were mapped and characterized phenotypically (Fig. 3) . As expected, insertions mapping within pBR322 DNA did not affect the Mcc+ Imm+ phenotype. The same occurred with five other mutants. Four of them harbored TnS in the HindIII C fragment from pMccC7, within the 3.2-kb region on the left. Close to vector sequences but on the right end of the HindlIl E fragment mapped the fifth insert that did not affect microcin functions. All the other 28 inserts impaired more or less either microcin C7 production or both immunity and production, and all of them were located along a continuous DNA stretch of 5.0 kb (Fig. 3) .
The microcin mutant plasmids could be classified in three groups according to their phenotypes. Mutants in the first group are Imm+ but produced reduced amounts of microcin. The four mutants in this group were indistinguishable by restriction analysis, and inserts were located 200 base pairs apart on the left of PstI (1) site (Fig. 3) in what we suppose to be one of the ends of the microcin C7 region. Mutants in the second group were Mcc-but expressed a weak immunity; they mapped within a DNA stretch we called y. Most mutants (the third group) were Mcc-Imm-, and the mutations were located in three different regions, a, ,B, and 8 (Fig.  3) . Although adjacent, a and , were considered different regions because a mutation mapping between them (the Tn5 insertion 13.5) did not affect immunity, and the mutant produced a very small amount of microcin.
Identification of two microcin C7 immunity determinants. Judging from cross-streak immunity tests, pMM560 determined immunity to microcin C7 as efficiently as wild-type plasmid pMccC7. However, pMM550, which includes the 1.85-kb PstI fragment present in pMM560 (see above), conferred a lower level of immunity. To gain insight on this unexpected result, we prepared new plasmids and looked at the immunity they conferred. First, we mutagenized pMM560 with transposon Tn5 to map more precisely the immunity determinant carried by this plasmid. We chose seven independent TnS derivatives for analysis. Figure 4A shows the location of the inserts and the phenotype conferred. In three of the Imm-derivatives the transposon mapped inside the fragment from pMccC7. In the other two, the site of insertion was mapped in the interrupted bla gene inside the part proximal to the bla promoter. These results indicated that the microcin immunity determinant in pMM560 was expressed by using the bla promoter. This was confirmed by inverting the direction of the microcin PstI fragment. The resulting plasmid (pMM561) did not express immunity at all.
Tn5 insertions within regions a, ,B, and 8 in pMM550 abolished immunity. Region at did not seem to be directly involved in immunity, because plasmid pMM570, obtained by elimination of the BgIII fragment, did not impair the level of immunity encoded by pMM550. Region is the one cloned in pMM560 which by conferring wild-type immunity defined a first immunity determinant.
The existence of a second immunity determinant in region 8 was suggested by the phenotype of the Tn5 inserts in this region and of the deleted derivative pMM572. It was further substantiated by the fact that plasmids lacking the first determinant could actually confer immunity on their host. In this case the presence of an efficient promoter in front of the determinant was also crucial to the expression of immunity. For instance, whereas no immunity could be detected in cells carrying pMM551, a moderate level of immunity was exhibited by those carrying pMM552 (Fig. 2) . In this plasmid, immunity might be expressed from the "antitet" promoter of pBR322, whose transcriptional initiation point is within the tet gene close to the HindIll site (7, 31) . A similar level of immunity was conferred by plasmid pCID111, which harbors the 2.4-kb Sacl C fragment from pMccC7 including this immunity determinant ( Fig. 1 and 3 ). This plasmid had been previously obtained by cloning pMccC7 Sacl fragments into vector pMM102 (15) . When the Sacl C fragment was inverted (pCID112) the immunity was completely lost, a result that was expected from our knowledge of the transcription in pMM102 (19) . Finally, we cloned the 2.55-kb HindIll fragment containing this immunity determinant in the HindIII site of vector pUC8 (33) . When the fragment was placed in the proper orientation to be transcribed from the lac promoter (pCID108) immunity was expressed as highly as with plasmid pMM560; no immunity could be detected when the fragment was in the opposite direction (pCID109) (Fig. 4B) . To map more precisely this determinant, we deleted the EcoRI fragment of pCID108. The resulting plasmid (pCID113), which only retained the 1,500-base-pair microcin fragment EcoRI-HindIII(3), was Imm- (Fig. 4B) . This means that the second microcin C7 immunity determinant begins in a point located between sites EcoRI and SacI(2), since plasmid pCID111, which only contains DNA sequences on the right of the SacI (2) A total of 20 independent Lac' mccC7-lacZ gene fusion plasmids were further analyzed. Insertion sites in pCID104 were mapped by digestion with BamHI and HindIII restriction endonucleases and taking into account the mini Mu dII1681 map in reference 9. When necessary, the location was verified with BglII or Sacl enzyme or both (Fig. 3) (2, 13, 14) . Like the other microcin-producing strains, BM7006 is immune to the microcin it produces. We show in this paper that the genetic determinants for microcin C7 production and immunity expression are borne on the 43-kb wild-type plasmid pMccC7. This plasmid has been found to be conjugative and incompatible with plasmid R6K, the prototype of the incompatibility group IncX (11) . It is a low-copy-number plasmid with polA-independent replication.
Two HindlIl-adjacent fragments of pMccC7, carrying the genetic information to produce microcin C7, were cloned in pBR322. The resulting plasmid, pMMS50, overproduced the antibiotic. This plasmid also coded for microcin immunity, but this function was expressed at a lower level than in wild-type pMccC7, a question to be discussed below. DNA insertions (TnS, Mu 1681) within a stretch of 5.0 kb from pMccC7 eliminated the ability of pMMSS0 to produce microcin. Most (Fig. 3) . Insertions in region -y eliminated the ability to produce microcin and decreased to a varied extent the expression of immunity. Region -y is probably required to produce microcin but not for immunity expression; immunity was probably impaired because DNA inserts exerted a polar effect on the expression of region 8, which, as indicated above, is involved in both microcin production and immunity expression. Region a is required for producing microcin but not for expressing immunity, because plasmid pMM570 (ABglII) was as immune as pMMSS0. Most probably TnS insertions in this region abolished immunity because the transposon exerted a polar effect on the expression of region 1 and perhaps B. Region 1, or part of it, is required for pMMSS0 to express immunity. This region must extend through the SacI(l) site because plasmid pMMS74 (ASacI)
was Imm- (Fig. 2 and 4A Consequently, all of our results suggest that the production of microcin C7 requires the activity of several adjacent genes (each region may contain one or more genes) located within a DNA segment of 5 kb. These genes seem to be organized as a polycistronic operon structure whose promoter is presumably located on the left side of the PstI (1) site (Fig. 2) .
Our results concerning microcin C7 immunity are rather surprising. Multicopy plasmids such as pMM550 and pCID104, which overproduce the antibiotic, confer less immunity than the low-copy-number plasmid pMccC7. In addition, the activities of two determinants borne by separate regions, M and 8, are required for pMMS50 to express immunity. However, any of these determinants by itself gives a very high level of immunity when expressed from strong promoters such as bla and lac. This dependence of the strength of the promoter was widely illustrated in Results. Whereas plasmids pMM554 and pMMS55, carrying the determinant in the p region, did not express immunity at all, pMM575 did express a low but significant level of immunity (Fig. 2) . This was likely due to the connection of the immunity determinant in , to a stronger promoter located on the left side of the BglII(1) site. It remains to be explained why the multicopy plasmids pMM550 and pCID104, which overproduce microcin, confer less immunity than pMccC7. This situation resembles that of tetracycline resistance encoded by transposon TnJO, which is expressed less when the transposon is present in a high copy number (12) . It is possible that overexpression of both immunity determinants, together in the same cell, leads to a decrease in the physiological expression of immunity as a whole. Alternatively, these hybrid plasmids may lack some genetic information that ensures a higher level of immunity from pMccC7. This question is being investigated.
The genetic system described in this work has several points in common with that coding for microcin B17 production and immunity. This last system also lies on a DNA segment of 5 kb, and four adjacent genes have been shown to be required to produce microcin B17 (28, 29) . Three genes are involved in the immunity expression, and two of them are also required to produce the antibiotic (M.C. Garrido et al., manuscript in preparation). One of the most intriguing points emerging from results described here and from our studies on microcin B17 is the involvement of the same gene product(s) in both the production of microcin and its immunity. We postulate that these products can intervene in the export of antibiotic outside cells. In this way bacteria could ensure production (output of the antibiotic) and protection against the microcin coming into cells. The existence of such an immunity mechanism does not preclude the existence of a other mechanisms working at other levels, for instance, by protecting the site of action of the antibiotic. This is probably what happens with microcin B17 (our unpublished results).
It would be of interest to know whether other microcin genetic systems are as complex as these and whether they are organized according to the same model.
